A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse
Study documentation
Trial StatusClosed for recruitment
DatesDate of activation: 23-Mar-09
Closed on : 12-Apr-13
Data management at EORTCMailbox
Randomized trialYes
Targeted Sample sizeEORTC Groups: 200 - All Groups: 1656
Number of steps1
Study StaffSteven Joniau (Study Coordinator) - U.Z. Leuven - Campus Gasthuisberg, Leuven
Richard Sylvester (Statistician) - EORTC Headquarters, Brussels
Maarten De Rouck (Data Manager) - EORTC Headquarters, Brussels
Sandrine Marreaud (Coordinating Physician) - EORTC Headquarters, Brussels
Julie Hermans (Project Manager) - EORTC Headquarters, Brussels, julie.hermans( at )eortc.be, +32 27741673
Type of cancerKidney
Participating GroupsUniversity College of London(Coordinating Group)
EORTC Genito-Urinary Cancers Group
Protocol summaryClinicalTrials.gov
NCT numberNCT00492258